CompletedPhase 2

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Canada30 participantsStarted 1994-05

Plain-language summary

RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Hormone therapy using tamoxifen may fight cancer by blocking the uptake of estrogen. Combining tamoxifen with chemotherapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cisplatin and doxorubicin together with tamoxifen works in treating patients with solid tumors.

Who can participate

Age range

65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Histologically proven soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer with clinical, radiological, or histologic evidence of incurability * Patients with thyroid cancer must have failed radioactive iodine * Measurable or evaluable disease PATIENT CHARACTERISTICS: Age: * 65 and under Performance status: * ECOG 0-2 Hematopoietic: * Granulocyte count at least 1,500/mm3 * Platelet count at least 140,000/mm3 Hepatic: * Bilirubin normal Renal: * Creatinine less than 1.47 mg/dL Cardiovascular: * Left ventricular ejection fraction at least 50% by MUGA scan * No congestive heart failure * No severe, uncontrolled hypertension * No ischemia, life-threatening arrhythmia, or conduction disturbance by ECG Other: * No allergy to study medications * No uncontrolled infection * No active abuse of ethanol that would preclude treatment * No other prior or concurrent malignancy * Not pregnant * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No more than 1 prior chemotherapy regimen * No prior anthracycline or cisplatin * At least 3 weeks since other prior chemotherapy and recovered Endocrine therapy: * Not specified Radiotherapy: * See Disease Characteristics * No prior radiotherapy to more than 25% of bone marrow * At least 3 weeks since other prior radiotherapy and recovered Surgery: * Not specified

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

Trial details

NCT IDNCT00002608

SponsorOttawa Regional Cancer Centre

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Adrenocortical Carcinoma trials